In addition to naming Acadia Pharma (NASDAQ: ACAD) one of his top partnership and acquisition (P&A) targets, as noted earlier ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE